



POSTER PRESENTATION

Open Access

# Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab

M Kulka\*, A Catalli

From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2009  
Halifax, Canada. 22-25 October 2009

## Background

IgE binding via the high affinity FcεRI receptor modulates FcεRI expression and cytokine production in mast cells. Antigen crosslinking of bound IgE further activates mast cells, inducing degranulation and inflammatory mediator release. Omalizumab (Xolair; Genentech Inc) is a recombinant human monoclonal anti-IgE antibody that prevents IgE binding to FcεRI.

## Objective

We investigated the effects of omalizumab on IgE-mediated responses in human mast cells.

## Methods

LAD2 and CD34<sup>+</sup>-derived human mast cell degranulation was determined by measuring the release of the granular enzyme, β-hexosaminidase. Toll-like receptor (TLR) expression was measured by quantitative (qPCR) and western blot analysis. IgE binding and FcεRI expression was determined by flow cytometry.

## Results

Omalizumab (10 ug/mL) inhibited IgE binding to LAD2 cells by 78% (P=0.007) compared to untreated control. Omalizumab (10 ug/mL) further blocked IgE-dependent upregulation of FcεRI expression by 90% (P=0.03). In addition, omalizumab removed FcεRI-bound IgE in a time-dependent manner; an effect that was detected as early as 24 hrs (57% removal; P<0.001) after addition of omalizumab resulting in a concomitant decrease in IgE-dependent FcεRI expression (30%; P<0.001). Omalizumab attenuated degranulation induced by anti-IgE crosslinking of bound IgE in a dose dependent manner, with 66% inhibition (P<0.0001) at 25 ug/ml. Furthermore, 100 ug/ml omalizumab prevented cysteinyl leukotriene

production and FcεRI-dependent modulation of TLR expression.

## Conclusions

Omalizumab inhibits IgE and IgE/anti-IgE dependent degranulation and receptor expression by human mast cells. Furthermore, omalizumab is able to remove pre-bound IgE from sensitized mast cells thereby reducing their response to FcεRI-dependent signals. This data suggests that omalizumab is an effective inhibitor of both sensitized and unsensitized human mast cells.

## Acknowledgements

Funded by a collaborative research grant from Genentech, Inc.

Published: 12 May 2010

doi:10.1186/1710-1492-6-S1-P13

Cite this article as: Kulka and Catalli: Inhibition of IgE and IgE/anti-IgE mediated responses in mast cells by Omalizumab. *Allergy, Asthma & Clinical Immunology* 2010 **6**(Suppl 1):P13.

Submit your next manuscript to BioMed Central  
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit



\* Correspondence: marianna.kulka@nrc-cnrc.gc.ca  
National Research Council- INH, Charlottetown, PE, Canada